We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
39 own
21 watching
Current Price
$3.06
$0.06
(2%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
147.48M
52-Week High
4.44
52-Week Low
1.26
Average Volume
0.24M
Dividend Yield
--
P/E Ratio
--
Market Capitalization147.48M
52-Week High4.44
52-Week Low1.26
Average Volume0.24M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
Depomed, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; and Lazanda (fentanyl) nasal spray, an intranasal fentanyl drug used to manage breakthrough pain in adults. The company also provides NUCYNTA ER (tapentadol extended release tablets), a product for the management of pain severe enough to long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults; and NUCYNTA (tapentadol), a product for the management of moderate to severe acute pain in adults. In addition, it is involved in the clinical development of Cebranopadol for the treatment of chronic nociceptive and neuropathic pain. The company sells its products to wholesalers and retail pharmacies. It also has a portfolio of license agreements based on its proprietary Acuform gastroretentive drug delivery technology with Mallinckrodt Inc.; Ironwood Pharmaceuticals, Inc.; and Janssen Pharmaceuticals, Inc. The company was founded in 1995 and is headquartered in Newark, California.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Globe Newswire
1month ago
WARREN, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of care to solve patients problems through simplifying complex delivery methods, announced today a transaction to license Sympazan (clobazam) oral film to...
Globe Newswire
1month ago
Trailing 12 Month Revenues of Sympazan Were $9.5 MillionAssertio Paid $9.0 Million Upfront, Additional $6.0 Million upon Patent Allowance LAKE FOREST, Ill., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (Assertio or the Company) (Nasdaq: ASRT), a specialty pharmaceutical company offering...
Accesswire
2 months ago
RALEIGH, NC / ACCESSWIRE / September 27, 2022 / The 2nd Annual MicroCap Rodeo Conference is going on the road and will take place at the Swissotel in Chicago on October 12th - 13th, 2022, where 60+ SmallCap, MicroCap and NanoCap public companies will be presenting to a global investor...
Globe Newswire
2 months ago
LAKE FOREST, Ill., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that Dan Peisert, CEO, will host investor meetings September 14, 2022 as part ...
Globe Newswire
3 months ago
Includes Full Exercise of Initial Purchaser's Option to Purchase $10 Million of Additional NotesLAKE FOREST, Ill., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, ...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$3.06
$0.06
(2%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00